NasdaqCM:NAGEPersonal Products
A Look At Niagen Bioscience (NAGE) Valuation After Q1 2026 Beat And Niagen Plus Telehealth Launch
Niagen Bioscience (NAGE) is back on investors’ radar after reporting Q1 2026 results that exceeded consensus estimates, alongside the launch of its Niagen Plus telehealth platform and at-home prescription injection kits.
See our latest analysis for Niagen Bioscience.
Despite the upbeat Q1 report and new Niagen Plus initiatives, the stock’s recent momentum has been weak, with a 30 day share price return of a 6.26% decline and a year to date share price return of a 32.96% decline. The 3 year...